XML 66 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
FAIR VALUE MEASUREMENTS (Tables)
3 Months Ended
Jun. 30, 2014
Fair Value Disclosures [Abstract]  
Schedule Of Financial Assets And Liabilities
The following tables present the Company’s financial assets and liabilities measured on a recurring basis using the fair value hierarchy as of June 30, 2014 and March 31, 2014 (in thousands).

Fair Value Measurements at
 
June 30, 2014
 
Level 1

Level 2

Level 3

Total
ASSETS:

 

 



Cash and cash equivalents
$
88,974

 
$

 
$

 
$
88,974

U.S. government and municipal obligations
40,929

 
74,565

 


115,494

Commercial paper

 
23,882

 


23,882

Corporate bonds
6,094

 

 


6,094

Derivative financial instruments

 
358

 


358


$
135,997

 
$
98,805

 
$


$
234,802

LIABILITIES:

 

 



Contingent purchase consideration
$

 
$

 
$
(4,369
)

$
(4,369
)
Derivative financial instruments

 
(102
)
 


(102
)

$

 
$
(102
)
 
$
(4,369
)

$
(4,471
)

Fair Value Measurements at
 
March 31, 2014
 
Level 1

Level 2

Level 3

Total
ASSETS:

 

 



Cash and cash equivalents
$
82,079

 
$
19,997

 
$


$
102,076

U.S. government and municipal obligations
21,992

 
69,765

 


91,757

Commercial paper

 
14,581

 


14,581

Corporate bonds
10,380

 

 


10,380

Derivative financial instruments

 
368

 


368


$
114,451


$
104,711


$


$
219,162

LIABILITIES:

 

 



Contingent purchase consideration
$

 
$

 
$
(4,291
)

$
(4,291
)
Contingent contractual non-compliance liability

 

 
(49
)

(49
)
Derivative financial instruments

 
(139
)
 


(139
)

$


$
(139
)

$
(4,340
)

$
(4,479
)
Reconciliation Of Changes In Fair Value Of Level III Financial Assets
The following table sets forth a reconciliation of changes in the fair value of the Company’s Level 3 financial liabilities for the three months ended June 30, 2014 (in thousands):

Contingent
Purchase
Consideration

Contingent
Contractual
Non-compliance
Liability
Balance at beginning of period
$
(4,291
)

$
(49
)
(Increase) / decrease in fair value and accretion expense (included within research and development expense)
(78
)

49

Balance at end of period
$
(4,369
)

$